Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine

Correlation between direct ELISA, single epitope-based inhibition ELISA and Pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine

(2011) Francis J. Dessy et al.   Human vaccines & immunotherapeutics

Comparison of the immunogenicity and safety ofCervarix™ andGardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years

(2010) Mark H. Einstein et al.   Human vaccines & immunotherapeutics

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

(2010) Silvia de Sanjose et al.   LANCET ONCOLOGY

Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women

(2010) N. De Carvalho et al.   VACCINE

HPV - immune response to infection and vaccination

(2010) Margaret Stanley   Infectious Agents and Cancer

Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses☆

(2009) Marie-Pierre David et al.   GYNECOLOGIC ONCOLOGY

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years

(2009)   LANCET

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

(2009) J Paavonen et al.   LANCET

Clinician's guide to human papillomavirus immunology: knowns and unknowns

(2009) Mark H Einstein et al.   LANCET INFECTIOUS DISEASES

HPV vaccines: are they the answer?

(2008) M. Stanley   BRITISH MEDICAL BULLETIN

Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: Improving upon nature

(2008) Tino F. Schwarz et al.   GYNECOLOGIC ONCOLOGY

Mechanisms of Human Papillomavirus Type 16 Neutralization by L2 Cross-Neutralizing and L1 Type-Specific Antibodies

(2008) P. M. Day et al.   JOURNAL OF VIROLOGY

Epidemiology and Natural History of Human Papillomavirus Infections and Type-Specific Implications in Cervical Neoplasia

(2008) F. Xavier Bosch et al.   VACCINE